ACN vs CNXC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CNXC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACN and CNXC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACN and CNXC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Accenture is a global professional services company that helps businesses, governments, and other organizations across more than 120 countries build digital infrastructure, optimize operations, and accelerate growth. The company operates across five major service areas: Strategy and Consulting, Technology Services, Operations, Industry X (engineering and manufacturing digitization), and Song (marketing and customer experience). It earns revenue through a mix of consulting engagements, managed services contracts, and increasingly fixed-price, outcome-based arrangements, with managed services growing faster at roughly 10% year over year as of Q2 FY2026. The company serves clients in virtually every major industry vertical, from financial services and health to communications and government, and generates the majority of its revenue outside North America.

Full ACN guide

Concentrix Corporation runs customer support, sales, trust-and-safety and back-office operations for large companies, staffing contact centers in dozens of countries and increasingly layering software and AI agents on top through its iX Suite. It was spun out of SYNNEX in December 2020 and roughly doubled in size by buying Webhelp in 2023. Revenue is close to $10 billion a year, spread across technology, retail and travel, banking and insurance, healthcare and other verticals, with long-tenured top clients (the company cites 16+ years average tenure for its top 25).

Full CNXC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACN drivers: Enterprise AI implementation at scale; Shift to recurring, outcome-based revenue.
• CNXC drivers: Selling AI into the installed base; Cash flow and deleveraging.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most structural bear-case concern is AI cannibalization: if generative AI and agentic AI tools automate the coding, testing, documentation, and process management that make up a significant portion of Accenture's billable work, clients may require fewer hours per engagement, compressing revenue without a commensurate reduction in costs. For CNXC, the core risk is that generative AI lets clients handle more customer contacts themselves or through AI-native vendors, shrinking the volume of paid human support faster than Concentrix can replace it with software revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACN if you believe its drivers more; CNXC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACN and CNXC guides.

ACN. Accenture's trailing P/E of roughly 10 to 13x represents a sharp discount to its own 5-year average of approximately 25x, a compression driven by AI cannibalization fears, federal spending headwinds, and a broader de-rating of large-cap professional services stocks rather than by any deterioration in underlying earnings, which have continued to grow. Operating margins near 17% and projected free cash flow of $10.8 billion to $11.5 billion in FY2026 reflect a business that is fundamentally sound and continuing to expand profitability. The elevated dividend yield above 3.5% (elevated because the share price has fallen roughly 38 to 40% over the prior 12 months) is now higher than Accenture's long-run average and is well covered by both earnings (roughly 52% payout ratio) and cash flows.

CNXC. On non-GAAP numbers CNXC trades at roughly 2.4x fiscal 2026 earnings and near 2.5x adjusted free cash flow, a valuation that prices in a sustained decline rather than stability. GAAP results show a net loss because of the ~$1.05B Q3 goodwill impairment, which is non-cash but tied directly to the lower stock price. Including debt, enterprise value is roughly $5.7B, or about 4x annualized non-GAAP operating income. For comparison, fiscal 2025 revenue was $9.83B (+2.2%), operating cash flow was $807M and adjusted free cash flow was $626M, so the 2026 cash guidance is roughly flat on a year earlier despite lower revenue. Management has said it expects fiscal 2027 adjusted free cash flow to be higher again, helped by lower restructuring costs, cash interest and capital spending. In June 2026 it had cut full-year non-GAAP EPS guidance to $10.83 to $11.18 from $11.48 to $12.07 and flagged about $175M of restructuring charges.

Headline figures (approximate, 2026-06-27): ACN shows revenue (ttm) ~$72 billion, revenue (fy2025, ended aug 31 2025) ~$69.7 billion (+7% YoY), q3 fy2026 revenue ~$18.7 billion (+5.6% YoY), q3 fy2026 eps (diluted) ~$3.82 (vs $3.52 in Q3 FY2025); CNXC shows revenue (ttm) ~$9.9B, fiscal 2026 revenue guidance ~$9.83B to $9.88B, non-gaap eps (fy2026 guidance) ~$10.97 to $11.09, market cap ~$1.6B (share price ~$26).

ACN and CNXC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACN and CNXC exposure against your real portfolio. It is not an investment adviser.